SUVEMCITUG

UNII:	T7Y5VC4ERJ
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	SUVEMCITUG
GSRS Full Record:	T7Y5VC4ERJ i

1610010-57-5
APX 003
APX-003
BD-0801
Immunoglobulin G1, anti-(human vascular endothelial growth factor) (human-Oryctolagus cuniculus monoclonal APX 003 γ1-chain), disulfide with human-Oryctolagus cuniculus monoclonal APX 003 κ-chain, dimer
Sevacizumab
Sevacizumab [WHO-DD]
Suvemcitug
immunoglobulin G1-kappa, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody (gamma1 heavy chain humanized (1-452) [VH (Homo sapiens IGHV3-21*01 (74.7%) -(IGHD) -IGHJ2*01 (92.9%), CDR-IMGT [9.8.14] (26-34.52-59.98-111)) (1-122) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (219) (123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363)(346-450), CHS (451-452)) (123-452)], (225-219')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (Homo sapiens IGKV1-6*01 (85.4%) -IGKJ4*01 (100%), CDR-IMGT [8.3.12] (27-34.52-54.91-102)) (1'-112') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (158), V101 (196)(113'-219')]; dimer (231-231'':234-234'')-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa)
suvemcitug [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

SUVEMCITUG

Synonyms and Mappings

Resources